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Abstract
Background: Increased iron stores are associated with increased risk of type 2 diabetes, however, the mechanisms
underlying these associations are poorly understood. Because a reduction of circulating osteocalcin levels after iron
overload have been demonstrated in cell cultures, and osteocalcin is related to glucose and insulin metabolism, the iron-
induced osteocalcin reductions could contribute to explain the role of iron metabolism in the development of type 2
diabetes mellitus.
Objective: To analyzed the associations between serum total and uncarboxylated osteocalcin and adiponectin
concentrations with serum ferritin and soluble transferrin receptor (sTfR) in elderly subjects.
Design: We evaluated a total of 423 subjects from the PREDIMED cohort in a population-based cross-sectional analysis.
Extensive clinical, nutritional and laboratory measurements, including total and uncarboxylated osteocalcin, adiponectin,
ferritin and sTfR were recorded.
Results: Serum ferritin was positively correlated with increased glucose and insulin circulating levels but also with HOMA-IR,
and was inversely associated with total osteocalcin and adiponectin. A regression analysis revealed that serum ferritin and
transferrin receptor levels were significantly associated with a decrease in total and uncarboxylated osteocalcin. Serum sTfR
levels were associated with lower uncarboxylated osteocalcin levels in the whole-study subjects and remained significant
only in the IFG (impaired fasting glucose) individuals.
Conclusions: We described, for the first time, an inverse association between serum ferritin and sTfR with osteocalcin and
extend previous results on adiponectin, thus supporting that factors related to iron metabolism could contribute to the
insulin resistance and the development of type 2 diabetes mellitus.
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Introduction
Iron is an essential mineral for humans although is potentially
hazardous in excess amounts. Excessive iron stores in patients with
hereditary hemochromatosis (HH) have been causally related with
the development of type 2 diabetes mellitus (T2DM) [1]. However,
moderately increased iron stores are also associated with
hyperglycemia and hyperinsulinemia, or an increased risk of type
2 diabetes mellitus in apparently healthy subjects [2–5]. These
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findings have been confirmed in a recent meta-analysis of five
prospective epidemiologic studies, giving a pooled RR of 1.63 for
type 2 diabetes mellitus in subjects with the highest levels of ferritin
[6]. Additionally, in a nested case-control study, increased soluble
transferrin receptor (sTfR) levels were associated with increased
T2DM risk (OR 2.26 [1.37–4.01] [7]. Increased iron stores have
also been associated with gestational diabetes [8], prediabetes [9],
central adiposity [10], metabolic syndrome [11], cardiovascular
disease [12] and osteopenia or osteoporosis [13,14].
Possible mediators linking iron stores and diabetes are still
poorly understood. Serum ferritin levels, the commonly used
marker for total body iron stores, has been associated with insulin
resistance measured by homeostasis model assessment (HOMA
IR) or hyperinsulinemic euglycemic clamp [15,16] but not with
pancreatic beta-cell function in humans [3], whereas in obese
mouse, dietary iron restriction protects from loss of beta cell
function [17]. Iron deposition in the muscle decreases glucose
uptake due to muscle damage [18] and it has additionally been
suggested that iron deposition in pancreatic b-cells impairs insulin
secretion in more advanced states of iron overload [19]. Despite
that, the effect of iron depots on other insulin-related tissues such
as adipose or bone tissues is far from clear. Recent studies
conducted in animals or in humans have demonstrated a direct
and causal effect of iron stores in circulating levels of adiponectin,
independently of other peripheral markers of inflammation
[20,21], thus explaining the attenuated association between ferritin
and incident type 2 diabetes mellitus observed after adjustment for
circulating adiponectin levels [5]. Additionally, a dose-response
decreased expression of genes related to the osteoblast phenotype,
including osteocalcin, after iron overload have been demonstrated
in cell cultures [22–24]. Thus, because osteocalcin (OC) has been
related to a decrease in fasting glucose concentrations and to an
increase of pancreatic beta-cell proliferation, insulin secretion and
sensitivity [25], the iron-induced osteocalcin reductions could
contribute to explain the role of iron overload in the development
type 2 diabetes mellitus.
To our best knowledge, there are no studies demonstrating a
direct association between markers of iron metabolism and
osteocalcin concentrations in humans. We therefore conducted
the present study to evaluate possible associations between serum
total and uncarboxylated osteocalcin concentrations with serum
ferritin and (sTfR) in elderly subjects at high cardiovascular risk.
Methods
Study design and population
For the present analysis, non-diabetic participants from three
Spanish centers (Reus-Tarragona, Navarra and Barcelona-Clinic)
within the framework of the PREDIMED study were randomly
selected. The PREDIMED study is a multicenter, randomized
clinical trial conducted in Spain to assess the effects of the
Mediterranean diet (MedDiet) on the primary prevention of
Table 1. Baseline characteristics of the study subjects.
Total subjects NGM IFG P
N 423 250 173
Men/women 202/221 111/139 91/82 0.097
Age (years) 66.360.3 66.360.4 66.260.4 0.902
BMI (kg/m2) 29.660.1 29.460.2 29.860.2 0.161
Waist circumference (cm) 99.0060.45 97.9460.60 100.4460.70 0.007
Total energy intake (Kcal/day) 2377.75628.78 2368.37637.20 2391.21645.53 0.707
Physical activity (METs-min/day) 273.4611.6 272.4615.3 274.9617.9 0.916
Smoking habit (yes/no) 96/327 59/191 37/136 0.757
Fasting glucose (mg/dL) 97.00 (89.01, 109.01) 90.00 (85.00, 95.29) 111.15 (105.00, 122.75) ,0.001
Total cholesterol (mg/dL) 223.2161.84 223.0762.22 223.4163.17 0.929
HDL cholesterol (mg/dL) 55.2960.67 56.6760.95 53.3060.89 0.014
LDL cholesterol (mg/dL) 139.6161.57 139.5962.02 139.6362.51 0.990
Triglyceride level (mg/dL) 141.8264.27 133.7364.51 153.5768.12 0.022
Fasting plasma insulin (mU/mL) 4.61 (3.12, 7.01) 4.23 (3.06,6.48) 5.04 (3.332,7.61) 0.037
HOMA-IR 1.3560.04 1.1460.04 1.6860.07 ,0.001
HOMA-BCF % 63.1262.88 77.3764.40 41.9361.87 ,0.001
Total osteocalcin (ng/mL) 8.00 (6.17,10.75) 8.50 (6.36, 11.52) 7.44 (5.78,9.64) 0.005
Uncarboxylated osteocalcin (ng/mL) 4.15 (2.38,6.06) 4.58 (2.59,6.80) 3.56 (2.15,5.46) 0.003
Ratio ucOC/OC 0.5860.02 0.6260.03 0.5360.03 0.077
Adiponectin (ng/mL) 8.30 (5.29,13.22) 9.15 (6.10,14.23) 6.98 (4.68,11.54) 0.001
C-Reactive Protein (ng/mL) 1.32 (0.26,3.58) 1.24 (0.22,3.17) 1.43 (0.31,3.90) 0.612
oxLDL (mU/L) 59.1761.26 60.5861.62 57.1162.01 0.150
Ferritin (ng/mL) 126.20 (67.98, 212.47) 118.85 (66.64, 204.75) 132.70 (75.38, 230.91) 0.104
Transferrin receptor (mg/L) 1.24 (1.07,1.42) 1.25 (1.09,1.43) 1.22 (1.07,1.41) 0.242
Ratio Transferrin/ferritin 0.01860.0012 0.01960.0018 0.01560.027 0.155
Data expressed as mean 6 SE, mean (IQR). P* are differences between normal glucose metabolism (NGM) and impaired fasting glucose (IFG) groups.
doi:10.1371/journal.pone.0076433.t001
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Figure 1. Correlations between serum ferritin levels and selected biochemical parameters. Correlation coefficients are based on loge-
transformed values of markers except HOMA-IR and HOMA-BCF.
doi:10.1371/journal.pone.0076433.g001
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cardiovascular disease. The design of the PREDIMED trial
(http://www.controlled-trials.com/ISRCTN35739639) has been
reported elsewhere [26,27], and it is available at http://www.
predimed.org and www.predimed.es. Subjects were men aged 55
to 80 years and women aged 60 to 80 years without prior
cardiovascular disease (CVD) at baseline but with at least three
cardiovascular risk factors namely: smoking, hypertension, dysli-
pidemia, overweight (Body mass index (BMI) $25 kg/m2), and a
family history of early-onset coronary heart disease (before age
55 years in men or before age 65 years in women) in first-degree
relatives [27]. The exclusion criteria for the PREDIMED study
were any severe chronic illness, alcohol or drug addiction, history
of food allergy to olive oil or nuts, or a low predicted likelihood of
changing dietary habits according to Prochaska and DiClemente’s
stages-of-change model [28].
We performed the current cross-sectional analyses at baseline
evaluation of a subsample of 455 subjects of this cohort, after
excluding 9 participants with very low values of serum ferritin who
were clearly outside the normality levels according to the cut-off of
our central laboratory to exclude individuals with ferropenia
(,10 ng/dL in women and,20 ng/dL in men). We also excluded
other 23 subjects with missing data on plasma glucose, insulin or
some important covariates for the analysis.
The PREDIMED study protocol was approved by the
institutional review boards of all the centres involved, and all
subjects agreed to participate in the study and gave their written
informed consent.
Measurements
Medical information was collected on subjects’ medical record
of a 47-item questionnaire about education, lifestyle, history of
illnesses and medication use. A validated 137-item food frequency
questionnaire (FFQ) was administered [29] and dietary energy
intake was calculated from Spanish food composition tables [30].
Trained personnel measured baseline weight, height and waist
circumference as previously reported, as well as blood pressure in
triplicate with a validated semiautomatic oscillometer (Omron
HEM-705CP, Hoofddorp, Netherlands). Enegy expenditure in
leisure-time physical activity (LTPA) was estimated using the
validated Spanish version of the Minnesota Questionnaire.
Blood samples were collected from all participants after an
overnight fast and were immediately processed, coded, and
shipped to a central laboratory. Serum levels of fasting glucose,
total cholesterol, HDL-cholesterol and triglycerides were mea-
sured by standard enzymatic automated methods. LDL-cholester-
ol concentrations were calculated using Friedewald’s equation in
those patients whose triglyceride levels were,400 mg/dL. Plasma
fasting insulin concentrations were measured by an ELISA kit for
human insulin (Millipore, St. Charles, Missouri, USA). Insulin
resistance was estimated by the HOMA method using the
following equation [31]: HOMA-IR = [fasting insulin (mIU/
mL) x fasting glucose (mmol/L)]/22.5. Serum total and un-
carboxylated osteocalcin levels were measured by electrochemilu-
minescence immunoassay (N-mid osteocalcin, Roche, Indianapo-
lis, IN); the intra- and inter-assay coefficients of variation were
,3.6% and ,6.6% respectively). Altered beta-cell function was
estimated using HOMA-BCF (homeostasis model assessment-beta
cell) as previously described [32]. Serum ferritin and soluble
transferrin receptor were measured by a particle-enhanced
immunoturbidimetric assay using the Hitachi analyzer and
sTfR:ferritin ratio was calculated. C-reactive protein (CRP)
concentrations were measured via a highly sensitive immunoassay
(Helica Biosystems Inc, Santa Ana, CA). Adiponectin levels were
measured using an enzymatic immunoassay (Millipore, St.
Charles, Missouri, USA). Plasma oxidized LDL (oxLDL) concen-
trations were also measured by a commercial ELISA (Mercodia
Oxidized LDL ELISA, Uppsala, Sweden).
Statistical analysis
Variables with skewed distribution according to the Kolmo-
gorov–Smirnov tests were loge-transformed before analysis. Means
(SE), percentages (%) or median (IQR) were used for descriptive
purposes. Whether the associations differed between sexes were
tested by adding the interaction terms sex*ferritin and sex*sTfR to
the fully adjusted models. Because no interaction was found, all
results are presented for the whole population studied. Although no
interaction was observed between markers of iron status and glucose
metabolism (IFG*ferritin and IFG*sTfR) it is physiologically
plausible that impaired fasting glucose (IFG) (considered when
fasting glucose levels were higher than 100 mg/dL) could affect the
associations between ferritin and sTfR with total and uncarboxy-
lated osteocalcin or adiponectina [33]. For this reason, results are
also presented stratified according to glucose metabolism for two
different groups: for subjects with normal glucose metabolism
(NGM) and for those with IFG. General characteristics of the study
subjects were compared between both sexes using ANOVA.
Associations between markers of iron metabolism (ferritin, trans-
ferrin receptor and the ratio sTfR:ferritin) and metabolic or
inflammatory variables were examined using Spearman’s correla-
tions. To examine the relationship between markers of iron
metabolism with total or uncarboxylated osteocalcin, linear
regression models were fitted including sex, age, BMI, smoking
status, total energy intake, energy expenditure in leisure-time
physical activity, fasting plasma glucose and insulin, and markers of
inflammation or oxidation (adiponectin, CRP, oxLDL) as poten-
tially confounding variables in the fully adjusted model. In addition,
both regressions analyses with either serum ferritin or sTfR as
outcomes were mutually adjusted for each other to account for
negative confounding because they are both independently associ-
ated with insulin resistance despite their negative reciprocal
correlation [16,34]. For loge-transformed outcome variables (i.e.
total and uncarboxylated osteocalcin) regression coefficients were
converted into percentages of relative change in the original variable
(percentage decrease in total or uncarboxylated osteocalcin per
50 ng/mL increase in ferritin or per 1 ng/mL of increased sTfR).
All analyses were performed using the SPSS 20.0 software (SPSS
Inc, Chicago, IL).
Results
General characteristics of the study subjects are reported in
Table 1. Total and uncarboxylated osteocalcin and adiponectin
were significantly lower in subjects with impaired fasting glucose.
A tendency to higher ferritin concentrations and a lower ratio of
sTfR:ferritin were observed in individuals with impaired fasting
glucose in comparison to those with normal glucose metabolism as
expected, although these differences didn’t reach statistical
significance.
In the whole-study population, serum ferritin was positively
correlated with increased glucose and insulin circulating levels but
also with HOMA-IR, and was inversely related with total and
uncarboxylated osteocalcin and adiponectin but not with HOMA-
BCF (Figure 1). Soluble transferrin receptor concentrations were
positively related with plasma oxLDL levels (r = 0.134, p = 0.006)
and non- related with plasma glucose (r =20.078, p = 0.113,
insulin (r = 0.003, p = 0.946), HOMAIR (r =20.032, p = 0.522)
and HOMA-BCF (r = 0.014, p = 0.771). A non-significant corre-
lation was observed between sTfR and ucOC (r =20.088,
Iron Metabolism and Osteocalcin
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p = 0.071), and between sTfR:ferritin and glucose, insulin and
HOMA-IR (r =20.154, r =20.177, r =20.194 p,0.001 for all).
Total OC and adiponectin were negative associated with
HOMA-IR (20.193 and 20.338, p,0.001 respectively). In
addition, ferritin and sTfR serum levels were inversely correlated
(r =20.250, p,0.001). In a linear regression model, serum ferritin
and transferrin receptor concentrations were significantly associated
with a decrease in total OC (p = 0.004) per 50 ng/mL of increased
Table 2. Association between markers of iron metabolism and total or uncarboxylated osteocalcin serum levels.
For each 50ng/mL of increased ferritin For each 1ng/mL of increased sTfR
For each 0.1 ng/mL of increased ratio
sTfRferritin
Outcome
Regression
coefficient 95% CI P-value
Regression
coefficient 95% CI P-value
Regression
coefficient 95% CI P-value
In the whole population
Total OC (ng/mL) (% change)
Crude 23.82 25.25, 22.27 ,0.001 28.05 219.42, 4.91 0.211 9.85 26.48,
29.04
0.250
Model 1 22.76 24.30, 21.09 0.001 26.76 217.96, 6.07 0.286 5.02 210.41,
23.24
0.543
Model 2 22.46 24.01, 20.79 0.004 212.97 223.73, 20.79 0.038 0.80 213.92,
18.05
0.921
Uncarboxylated OC (ng/mL) (% change)
Crude 21.98 24.49, 0.70 0.140 217.05 233.16, 2.83 0.088 7.03 217.79,
39.37
0.612
Model 1 20.29 22.95, 2.53 0.859 217.55 233.30, 2.02 0.075 22.95 225.54,
26.49
0.825
Model 2 20.39 23.24, 2.42 0.765 222.11 237.76, 22.56 0.029 25.25 227.45,
23.86
0.694
In the NGM
Total OC (ng/mL) (% change)
Crude 24.11 26.26, 21.98 ,0.001 214.27 227.31, 1.00 0.066 0.60 216.80,
21.65
0.951
Model 1 22.95 25.25, 20.59 0.013 210.05 223.58, 5.86 0.200 0.002 217.30,
20.92
0.998
Model 2 22.95 25.06, 20.69 0.010 216.13 229.03, 20.98 0.038 24.87 221.25,
14.91
0.603
Uncarboxylated OC (ng/mL) (% change)
Crude 20.99 24.78, 2.94 0.620 216.97 237.12,
9.52
0.186 21.39 228.46,
35.79
0.929
Model 1 1.00 23.05, 5.01 0.644 214.61 235.07, 12.29 0.257 29.87 234.62,
24.11
0.521
Model 2 0.40 23.72, 4.81 0.815 216.13 237.37, 12.29 0.236 210.05 235.20,
24.85
0.542
In the IFG
Total OC (ng/mL) (% change)
Crude 23.14 25.16,
20.98
0.005 0.90 218.86, 25.35 0.939 32.04 22.37,
78.42
0.071
Model 1 22.37 24.59,
20.19
0.036 21.29 220.30, 22.14 0.901 15.83 214.78,
57.45
0.345
Model 2 22.17 24.49,
0.30
0.080 27.03 225.91, 16.64 0.526 14.50 215.88,
55.89
0.386
Uncarboxylated OC (ng/mL) (% change)
Crude 22.27 25.63,
1.10
0.183 222.81 244.95,8.22 0.132 20.44 225.09,
93.67
0.441
Model 1 21.39 24.87,
2.32
0.468 225.53 248.31, 1.51 0.061 3.97 236.36,
69.89
0.875
Model 2 22.07 25.82,
1.91
0.308 234.29 254.38, 25.35 0.024 3.35 237.37,
70.57
0.897
b values are unstandardized regression coefficients and represents the change in total and uncarboxylated osteocalcin according to increases in ferritin, soluble
transferrin receptor and the ratio of sTfR/ferritin. Model 1: adjusted for sex, age and BMI, smoking status, total energy intake and energy expenditure in leisure-time
physical activity. Model 2: additionally adjusted for fasting plasma glucose, insulin and markers of inflammation and oxidative stress (adiponectin, C-reactive protein,
oxidized LDL) and ferritin and transferrin receptor adjusted for each other).
doi:10.1371/journal.pone.0076433.t002
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ferritin, and a decrease in uncarboxylated osteocalcin (ucOC)
(p = 0.038) per 1 ng/mL of increased sTfR even after adjustment for
sex, age, BMI, smoking status, total dietary energy intake, physical
activity, fasting plasma glucose, and insulin, and peripheral markers
of inflammation and oxidation (adiponectin, CRP, oxLDL), and
sTfR or serum ferritin (for models with ferritin or TfR as the
outcome, respectively). These associations were apparent both in
normoglycemic and in subjects with impaired fasting glucose,
although in the last case the association between ferritin and total
OC was not statistical significance (p = 0.080). Serum sTfR levels
were associated with lower ucOC levels in the whole-study subjects
and remained significant only in the IGM individuals (Table 2). In
contrast, sTfR:ferritin ratio was not significantly associated nor with
total OC neither with ucOC.
Discussion
The present study confirmed, for the first time, that both serum
ferritin and soluble TfR levels, as markers of iron metabolism, are
independently and inversely associated with total and uncarboxy-
lated osteocalcin. Because osteocalcin has been related not only
with bone metabolism but also with insulin resistance and
sensitivity, our results would help to explain one of the possible
mechanisms relating iron metabolism, insulin resistance and risk of
type 2 diabetes mellitus. We also confirm and extend previous
results showing the inverse association between serum ferritin and
adiponectin concentrations as a potential mechanism linking iron
stores with insulin resistance [21,35].
Serum OC levels were used to evaluate bone metabolism
because it has been considered a better sensitive marker of bone
formation than serum alkaline phosphatase. However, increasing
data supporting extra-skeletal roles of OC have emerged, being
widely accepted its hormonal effect on energy metabolism,
angiogenesis or insulin metabolism [36]. In this sense, mice
lacking osteocalcin show lower beta-cell proliferation, glucose
intolerance, and insulin resistance than wild-type mice [15].
Additionally, osteocalcin knockout mice have reduced levels of
serum adiponectin, which suggests a potential role for osteocalcin
in insulin sensitivity and secretion. In a previous study, our group
demonstrated, for the first time, that increased total or
uncarboxylated OC serum concentrations were directly associated
with HOMA-BCF and inversely with insulin resistance deter-
mined by HOMA-IR [25].
Iron overload can damage several important organs such as
liver, pancreas and heart. Many lines of evidence indicated that
iron overload affects bone tissue causing both osteopenia and
osteoporosis [37]. Addition of iron to a culture of human
osteoblasts decreased osteocalcin concentrations dose-responsive-
ly. This has been attributed to the ferroxidase activity of ferritin
rather than its iron sequestering capacity [24]. Furthermore, iron
exposure on human osteoblast-like cells reduced the expression of
genes involved in bone matrix formation or osteoblast differen-
tiation such as COL1AI, Runx2 or osteocalcin [23,38]. The
observed inverse associations of ferritin with total and uncar-
boxylated osteocalcin observed in our study, independently of
other inflammatory markers and glucose metabolism status,
extend the results obtained in vitro. Given that ferritin is
inversely correlated with sTfR we expected a negative relation-
ship between sTfR uncarboxylated osteocalcin rather than the
negative observed in our study. However, our results are in
agreement to those reported by Rajpathak and coworkers who
observed, in a nested case-control study conducted in the
framework of the Diabetes Prevention Program, a positive
association between serum sTfR levels and T2DM risk even
after adjusting by ferritin levels, thus suggesting another potential
mechanism linking sTfR and T2DM unrelated to iron overload
[7]. Increased levels of sTfR have been observed in vitro after
insulin administration to rats (32) and it cannot be discard sTfR
levels as a biomarker of other factors causally related to T2DM
[7]. In our study subjects, sTfR levels could be the result of a
compensatory mechanism for a reduction of free iron levels
secondary to inflammatory or oxidative status common in old
subjects at cardiovascular risk. Moreover, in addition to other
epidemiological studies, we also showed positive associations of
ferritin and sTfR with fasting glucose, insulin and HOMA-IR,
but not with HOMA-BCF, suggesting that the contribution of
iron metabolism to type 2 diabetes mellitus is basically related to
the induction of insulin resistance more than through an effect
on beta-cell function [3,15]. In contrast to previous prospective
studies suggesting that lower ratios of sTfR: ferritin were
associated with increased risk of type 2 diabetes [2,4], no impact
on the association of sTfR:ferritin and osteocalcin or adiponectin
was observed in our study. However, as expected, we observed a
negative tendency in the association between this ratio and
HOMA-IR.
Iron stores could also induce insulin resistance through induction
of oxidative stress [39] and serum ferritin has been associated with
circulating oxidized LDL lipoproteins and advanced oxidation
products [40]. Nevertheless, we observed a significant relationship of
iron markers and osteocalcin or adiponectin independently of
oxidized LDL, suggesting that the associations between iron and
insulin resistance could be additionally mediated by other pathways
rather than oxidative stress.
One concern of the present study is that ferritin concentrations
may reflect other physiological aspects rather than iron storage,
especially subclinical systemic inflammation related to insulin
resistance. This is more relevant in our subjects because they are
old, obese and at high cardiovascular risk. The cross-sectional
nature of our assessment also hinders the possibility of a proper
ascertainment of the direction of the causal sequence and we
acknowledge this limitation. Also, because the associations
between iron metabolism and osteocalcin forms observed in our
study are weak, we must be cautious to consider iron metabolism
markers as predictors of osteocalcin levels. Therefore, further
prospective investigations should be designed to confirm these
associations.
We tried to minimize the potential confounding by obesity and
inflammation controlling for BMI and oxidative and inflammatory
status (CRP, adiponectin, oxLDL) in the multivariate models.
However, we cannot rule out the possibility that our results may have
been influenced by other unmeasured factors. In any case, the high
cardiovascular risk of our study subjects is to our advantage because
they are a homogeneous population with smaller between-subjects
variability in cardiovascular risk factors than a sample of the general
population.
In sum, we described an inverse association between serum
ferritin and sTfR with total or uncarboxylated osteocalcin and
adiponectin in subjects at high cardiovascular risk. These findings
suggest that body iron metabolism may contribute to the induction
of insulin resistance through the inhibition of adiponectin and
osteocalcin thus providing support for the hypothesis that iron
metabolism could contribute to the origin of type 2 diabetes mellitus.
Further research is warranted to understand the exactly mechanisms
by which ferritin and sTfR levels induce insulin resistance.
Iron Metabolism and Osteocalcin
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